Guardant Health, Inc. (GH)

Market Cap	8.41B
Revenue (ttm)	828.85M
Net Income (ttm)	-413.82M
Shares Out	124.71M
EPS (ttm)	-3.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,774,099
Open	64.78
Previous Close	64.47
Day's Range	64.67 - 67.51
52-Week Range	20.14 - 67.51
Beta	1.44
Analysts	Strong Buy
Price Target	57.50 (-14.71%)
Earnings Date	Jul 30, 2025

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 2,021
• Stock Exchange: NASDAQ
• Ticker Symbol: GH
• Website: https://guardanthealth.com

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Analyst Summary

According to 16 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $57.5, which is a decrease of -14.71% from the latest price.

Price Target

$57.5

(-14.71% downside)

Analyst Consensus: Strong Buy